Similar articles

• Plasma-level studies of chlorpromazine following the administration of chlorpromazine hydrochloride and chlorpromazine embonate in chronic schizophrenics.

  Cooper SF, Albert JM, Hillel J, Caille G. Cooper SF, et al. Curr Ther Res Clin Exp. 1973 Feb;15(2):73-7. Curr Ther Res Clin Exp. 1973. PMID: 4632509 Clinical Trial. No abstract available.
• [Clinical significance of pattern of blood chlorpromazine and its metabolite levels and prediction of response to chlorpromazine treatment--studies on the rational pharmacotherapy in schizophrenics (author's transl)].

  Sakurai Y, Nakahara T, Ikenaga H, Takahashi R. Sakurai Y, et al. Seishin Shinkeigaku Zasshi. 1978 Jul;80(7):405-24. Seishin Shinkeigaku Zasshi. 1978. PMID: 724820 Japanese. No abstract available.
• Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report.

  Stimmel GL, Falloon IR. Stimmel GL, et al. J Clin Psychiatry. 1983 Nov;44(11):420-2. J Clin Psychiatry. 1983. PMID: 6643405
• Interpatient variation and significance of plasma levels of chlorpromazine in psychotic patients.

  March JE, Donato D, Turano P, Turner WJ. March JE, et al. J Med. 1972;3(3):146-62. J Med. 1972. PMID: 4508254 No abstract available.
• Fluphenazine decanoate trial in chronic in-patient schizophrenics failing to absorb oral chlorpromazine.

  Adamson L, Curry SH, Bridges PK, Firestone AF, Lavin NI, Lewis DM, Watson RD, Xavier CM, Anderson JA. Adamson L, et al. Dis Nerv Syst. 1973 Apr-May;34(4):181-91. Dis Nerv Syst. 1973. PMID: 4711886 No abstract available.